Pharmamar : Seguirá los Pasos al Alza de Faes. Objetivo 1,75 euros.

Leiomyosarcoma . A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma

Science Direct , en su edición de Abril 2019 , publica un Extenso Articulo en el que se Presentan los Resultados de un Ensayo Inicial para el Tratamiento de Leiomyosarcomas Modelo PDOX con varios de los actuales Farmacos : Yondelis , Gemcitabine combinado con Docetaxel , Temozolomide , Doxorubicin , Pazopanib y Olaratumab .

Resultaron Altamente Efectivos : Yondelis , Gemcitabine  combinado con Docetaxel y Temozolomide . 

El resto de Fármacos ( Pazopànib , Olaratumab y Doxorubin ) resultaron Ineficazes . A tener en cuenta que  Doxorubicina resulta ser el Tratamiento Actual en Primera línea .

***************************

Pharmacological Research , Volume 142, April 2019, Pages 169-175.

A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent Leiomyosarcoma .


Authors

Zhang Z1, Hu K2, Kiyuna T3, Miyake K3, Kawaguchi K3, Igarashi K3, Nelson SD4, Li Y4, Singh SR5, Hoffman RM6.
Author information
1
AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA 92111, USA; Department of Surgery, University of California San Diego, CA 92103, USA; Department of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China.
2
Department of Oncology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China.
3
AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA 92111, USA; Department of Surgery, University of California San Diego, CA 92103, USA.
4
Department of Pathology, University of California, Los Angeles, CA 90095, USA.
5
Basic Research Laboratory, National Cancer Institute, Frederick, MD 21702, USA.
6
AntiCancer, Inc., 7917 Ostrow Street, San Diego, CA 92111, USA; Department of Surgery, University of California San Diego, CA 92103, USA.

Abstract

Leiomyosarcoma is a rare and recalcitrant disease. Doxorubicin (DOX) is usually considered first-line treatment for this disease, but frequently is ineffective. In order to individualize therapy for this and other cancers, we have developed the patient-derived orthotopic xenograft (PDOX) mouse model. In the present study, we implanted a recurrent leiomyosarcoma from a resected tumor from the patient's thigh into the femoral muscle of nude mice.

The Following Drugs Were Tested on the Leiomyosarcoma PDOX Model: DOX, The Combination of Gemcitabine (GEM) and Docetaxel (DOC), Trabectedin (TRA), Temozolomide (TEM), Pazopanib (PAZ) and Olaratumab (OLA). 

Of These Agents GEM/DOC, TRA and TEM Were Highly Effective in the Leiomyosarcoma PDOX model, The Other Agents, Including First-Line Therapy DOX,Were Ineffective.

Thus the leiomyosarcoma PDOX model could precisely distinguish effective and ineffective drugs, demonstrating the potential of the PDOX model for leiomyosarcoma.

Copyright © 2019. Published by Elsevier Ltd.